Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective Randomised Phase III Study Of Androgen Deprivation Therapy With Or Without Docetaxel With Or Without Local Radiotherapy With Or Without Abiraterone Acetate And Prednisone In Patients With Metastatic Hormone-Naïve Prostate Cancer

Next Previous
Trial Profile

A Prospective Randomised Phase III Study Of Androgen Deprivation Therapy With Or Without Docetaxel With Or Without Local Radiotherapy With Or Without Abiraterone Acetate And Prednisone In Patients With Metastatic Hormone-Naïve Prostate Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abiraterone acetate (Primary) ; Docetaxel; LHRH receptor agonists; LHRH receptor antagonists; Prednisone
  • Indications Adenocarcinoma; Liver metastases; Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms GETUG AFU 21; PEACE1

    • Most Recent Events

    • 06 Jun 2023 Results of meta analysis from ARASENS, PEACE-1, ENZAMET, presented at the 59th Annual Meeting of the American Society of Clinical Oncology
    • 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
    • 18 Feb 2023 Results of post hoc analysis assessing the safety and efficacy of abiraterone acetate + prednisone (AAP) in older (greater than 70 years) and younger (Less than 70 years) patients in PEACE-1 presented at the 2023 Genitourinary Cancers Symposium
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top